"Goserelin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.
Descriptor ID |
D017273
|
MeSH Number(s) |
D06.472.699.327.740.320.340 D12.644.400.400.740.320.340 D12.644.456.460.315 D12.644.548.365.740.320.340 D12.776.631.650.405.740.320.340
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Goserelin".
Below are MeSH descriptors whose meaning is more specific than "Goserelin".
This graph shows the total number of publications written about "Goserelin" by people in this website by year, and whether "Goserelin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
1997 | 0 | 1 | 1 |
2003 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Goserelin" by people in Profiles.
-
Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. J Clin Oncol. 2003 Apr 01; 21(7):1238-48.
-
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst. 1997 Jan 15; 89(2):158-65.
-
Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 1995 Apr; 45(4):616-23.